Efficacy and safety of Sinovac vaccine administered in patients undergoing hemodialysis

Davut Akin; Sehmus Ozmen; Ahmet Caliskan; Tugba Sari

doi:10.3855/jidc.17188

Efficacy and safety of Sinovac vaccine administered in patients undergoing hemodialysis

Authors

Davut Akin Pamukkale University School of Medicine, Department of Nephrology, Denizli, Turkey https://orcid.org/0000-0002-9567-7940
Sehmus Ozmen Medipol University, Camlica Hospital Department of Nephrology, Istanbul, Turkey
Ahmet Caliskan Pamukkale University School of Medicine, Department of Medical Microbiology, Denizli, Turkey https://orcid.org/0000-0002-1156-3787
Tugba Sari Pamukkale University School of Medicine, Department of Infectious Diseases, Denizli, Turkey https://orcid.org/0000-0003-3204-2371

DOI:

https://doi.org/10.3855/jidc.17188

Keywords:

COVİD-19, hemodialysis, treatment, Sinovac, vaccine

Abstract

Introduction: COVİD-19 disease is more serious and fatal in patients on dialysis treatment due to their immunosuppressive status. In this study, we aimed to evaluate the protection and safety of Sinovac vaccine, which is an inactivated vaccine, in patients undergoing hemodialysis.

Methodology: A control group consisting of 220 hemodialysis patients (HD group) and 648 healthcare professionals who were healthy in our institution were included in the study. Quant II IgG anti-Spike antibody was measured 3 weeks after two doses of Sinovac vaccine were administered to both groups.

Results: The antibody response after two doses of Sinovac vaccine was 85.2% in the HD group and 99.8% in the control group. The mean antibody level before vaccination in the HD group was 3.5 ± 7.2 AU/mL and increased significantly 3 weeks after two doses of vaccine (mean 751 ± 1196 AU/mL). The control group’s mean antibody level after vaccination was 1723 ± 1878 AU/mL. The mean antibody level after vaccination in the control group was significantly higher than the HD group (p < 0.0001). Despite higher levels of anti-Spike antibodies in the control group, post-vaccination antibody response was acceptable in both HD and control groups. The HD group was significantly older (mean 64 ± 12 years) than the control group (36 ± 10 years) (p < 0.0001).

Conclusions: Although dialysis patients are immunocompromised, and some may not develop antibodies to the virus as strongly as healthy people, this study revealed that dialysis patients developed significant amounts of antibodies. Being old or on dialysis is an independent predictor of low antibody response to the Sinovac vaccine.

Downloads

Published

2022-12-31

How to Cite

Akin D, Ozmen S, Caliskan A, Sari T (2022) Efficacy and safety of Sinovac vaccine administered in patients undergoing hemodialysis. J Infect Dev Ctries 16:1821–1825. doi: 10.3855/jidc.17188

Download Citation

Endnote/Zotero/Mendeley (RIS)

Issue

Vol. 16 No. 12: December 2022

Section

Coronavirus Pandemic

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).